Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Aroa Biosurgery's Symphony Reimbursement Rate Maintained for 2027

ARX: $0.505 -4.72% · MC: $179M

US Medicare and Medicaid authorities have maintained the existing outpatient reimbursement rate for Aroa Biosurgery's Symphony wound-care product for 2027. The same rate will also apply to non-sheet products in physicians' offices, which Aroa says creates an opportunity for other versions of its technology. The company's primary focus remains Myriad in hospital inpatient settings, where reimbursement is unaffected by the outpatient changes.

Source announcements: 2026-11-09 15:32 to 2026-11-09 15:32 Sydney time
Story updated 2026-11-09 16:19 Sydney time
SourcesUS CMS Confirms Symphony Outpatient Reimbursement Rate
Comments